Mild to moderate depression
Conditions
Interventions
Experimental group:The daily oral dose of Chaihu Anxin Capsule is the recommended dose
Placebo control group:Patients were given placebo with Chaihu Anxin Capsule orally every day, and the dose was the same as that of the experimental group
Sponsors
The First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Be between the ages of 18 and 65; 2.Confirmed diagnosis of mild to moderate depression (F32.0 or F32.1) according to the diagnostic criteria of the International Classification of Diseases and Classification of Diseases (ICD-10); HAMD-24 score between 8 and 35; 3.Patients with stable symptoms, who can understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Have a severe psychiatric illness (e.g., bipolar disorder, schizophrenia) or organic encephalopathy; 2.Patients with hypersensitivity to the study drug or its components; 3.Patients who are currently receiving other antidepressant therapy or participating in other clinical trials; 4.Pregnant or lactating women; 5.Patients with a suicide attempt or serious suicide risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Rating Scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale score;Liver function;Renal function;TCM Syndrome Assessment Scale score; | — |
Countries
China
Contacts
Public ContactJing Yu
The First Hospital of Hebei Medical University
Outcome results
None listed